Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos

Dow Jones02-24

By Colin Kellaher

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.

Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.

Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies.

Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug.

Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer.

Pfizer is developing several ADCs, which work like guided missiles by pairing antibodies with toxic agents to fight cancer.

Shares of Summit were recently up 7.3% at $23.73 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 24, 2025 06:44 ET (11:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2513408847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513408847","market":"us","top_or_hot":-1,"title":"Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors. \n</p>\n<p>\n  Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations. \n</p>\n<p>\n  Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies. \n</p>\n<p>\n  Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug. \n</p>\n<p>\n  Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer. \n</p>\n<p>\n  Pfizer is developing several ADCs, which work like guided missiles by pairing antibodies with toxic agents to fight cancer. \n</p>\n<p>\n  Shares of Summit were recently up 7.3% at $23.73 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 06:44 ET (11:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-24 19:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors. \n</p>\n<p>\n  Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations. \n</p>\n<p>\n  Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies. \n</p>\n<p>\n  Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug. \n</p>\n<p>\n  Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer. \n</p>\n<p>\n  Pfizer is developing several ADCs, which work like guided missiles by pairing antibodies with toxic agents to fight cancer. \n</p>\n<p>\n  Shares of Summit were recently up 7.3% at $23.73 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 06:44 ET (11:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2513408847","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513408847","pubTimestamp":1740397440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies.Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug.Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer.Pfizer is developing several ADCs, whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ADC":"艾格里房产","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","BK1161":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","BK4581":"高盛持仓","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LENZ":"Therapeutics","SMMF":"Summit Financial Group","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","SMMT":"Summit Therapeutics PLC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK1574":"生物医药B类股","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0234572021.USD":"高盛美国核心股票组合Acc","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","09926":"康方生物","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4592":"伊斯兰概念","PFE":"辉瑞","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","MRK":"默沙东","BK4559":"巴菲特持仓","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4568":"美国抗疫概念","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H"},"translate_title":"Summit Therapeutics与辉瑞将研究Ivonescimab/ADC组合","themeId":"aff2b842ffb31583ad6b861b733c603d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"PFE":1,"MRK":0.61,"SMMF":1,"LENZ":1,"SMMT":0.9,"09926":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors. \n\n\n  Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations. \n\n\n  Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies. \n\n\n  Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug. \n\n\n  Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer. \n\n\n  Pfizer is developing several ADCs, which work like guided missiles by pairing antibodies with toxic agents to fight cancer. \n\n\n  Shares of Summit were recently up 7.3% at $23.73 in premarket trading. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 06:44 ET (11:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2513408847","isCrawlerRequest":true}